[
  {
    "ts": "2025-12-05T01:15:00+00:00",
    "headline": "Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)",
    "summary": "PRINCETON, N.J., December 05, 2025--BMS's Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)",
    "url": "https://finance.yahoo.com/news/bristol-myers-squibb-breyanzi-approved-011500527.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "be3f7559-4bc4-3429-b76f-84bffe5fcc85",
      "content": {
        "id": "be3f7559-4bc4-3429-b76f-84bffe5fcc85",
        "contentType": "STORY",
        "title": "Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)",
        "description": "",
        "summary": "PRINCETON, N.J., December 05, 2025--BMS's Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)",
        "pubDate": "2025-12-05T01:15:00Z",
        "displayTime": "2025-12-05T01:15:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/bb2286ed2f0bcc352700e20a2b4d6884",
          "originalWidth": 480,
          "originalHeight": 320,
          "caption": "Product image for download (Photo: Bristol Myers Squibb)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8OaCGv9qJtwcUw0gllRSKg--~B/aD0zMjA7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/bb2286ed2f0bcc352700e20a2b4d6884.cf.webp",
              "width": 480,
              "height": 320,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.vXnBRdM8psBefdqqhnW9g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/bb2286ed2f0bcc352700e20a2b4d6884.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-squibb-breyanzi-approved-011500527.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-squibb-breyanzi-approved-011500527.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]